Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...

In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for ...

The detection of certain cardiac issues in a study of healthy volunteers led Aardvark to pause a Phase 3 trial only months before an expected data readout.

The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved ...

The regimen’s clearance in early multiple myeloma was the third approval under the agency’s controversial “national priority” voucher program and issued only 55 days after the review began.

In his lengthy address Tuesday night, the president touted his efforts to make drugs and insurance more affordable but ...

Cell therapy manufacturing is uniquely vulnerable to contamination, variability, and operational burden because the product - ...

Ingram, who steered the company through multiple drug approvals and controversies, will step aside as Sarepta faces dwindling ...

Yuviwel, a once-weekly injection, will now compete for market share with BioMarin’s lucrative daily shot Voxzogo.

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

The result “pulls the rug” out from under giredestrant, according to one analyst, sparking another share selloff following disappointing obesity data last week.

Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme ...